Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The combined company's MALT1 inhibitor has started phase 1.
Crunch time approaches for UroGen.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
